AU2002336124B2 - Biologically active peptides and their use for repairing injured nerves - Google Patents
Biologically active peptides and their use for repairing injured nerves Download PDFInfo
- Publication number
- AU2002336124B2 AU2002336124B2 AU2002336124A AU2002336124A AU2002336124B2 AU 2002336124 B2 AU2002336124 B2 AU 2002336124B2 AU 2002336124 A AU2002336124 A AU 2002336124A AU 2002336124 A AU2002336124 A AU 2002336124A AU 2002336124 B2 AU2002336124 B2 AU 2002336124B2
- Authority
- AU
- Australia
- Prior art keywords
- kdi
- spinal cord
- peptide
- tripeptide
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 136
- 210000005036 nerve Anatomy 0.000 title claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 23
- 210000000278 spinal cord Anatomy 0.000 claims description 89
- 241001465754 Metazoa Species 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 208000014674 injury Diseases 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 210000000578 peripheral nerve Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 210000002241 neurite Anatomy 0.000 abstract description 32
- 108010057670 laminin 1 Proteins 0.000 abstract description 24
- 230000001537 neural effect Effects 0.000 abstract description 10
- 230000008929 regeneration Effects 0.000 abstract description 10
- 238000011069 regeneration method Methods 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241000282414 Homo sapiens Species 0.000 description 85
- 210000002569 neuron Anatomy 0.000 description 75
- 210000004498 neuroglial cell Anatomy 0.000 description 35
- 230000014511 neuron projection development Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 24
- 210000003169 central nervous system Anatomy 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 210000004885 white matter Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 230000002490 cerebral effect Effects 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- 108010085895 Laminin Proteins 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000001423 neocortical effect Effects 0.000 description 9
- 102000008763 Neurofilament Proteins Human genes 0.000 description 8
- 108010088373 Neurofilament Proteins Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000002518 glial effect Effects 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 210000005044 neurofilament Anatomy 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 210000000478 neocortex Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000009065 Netrin-1 Human genes 0.000 description 3
- 108010074223 Netrin-1 Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000004009 axon guidance Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005230 lumbar spinal cord Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000011201 multiple comparisons test Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical class Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241001492222 Epicoccum Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108010063605 Netrins Proteins 0.000 description 1
- 102000010803 Netrins Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940089027 kcl-40 Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20012082A FI20012082A0 (fi) | 2001-10-26 | 2001-10-26 | Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi |
| FI20012082 | 2001-10-26 | ||
| PCT/FI2002/000831 WO2003035675A1 (en) | 2001-10-26 | 2002-10-25 | Biologically active peptides and their use for repairing injured nerves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002336124A1 AU2002336124A1 (en) | 2003-07-03 |
| AU2002336124B2 true AU2002336124B2 (en) | 2008-07-03 |
Family
ID=8562134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002336124A Ceased AU2002336124B2 (en) | 2001-10-26 | 2002-10-25 | Biologically active peptides and their use for repairing injured nerves |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20040266991A1 (https=) |
| EP (1) | EP1438329B1 (https=) |
| JP (1) | JP4312054B2 (https=) |
| AT (1) | ATE490972T1 (https=) |
| AU (1) | AU2002336124B2 (https=) |
| CA (1) | CA2465245C (https=) |
| DE (1) | DE60238551D1 (https=) |
| DK (1) | DK1438329T3 (https=) |
| FI (1) | FI20012082A0 (https=) |
| WO (1) | WO2003035675A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005029468A1 (de) * | 2005-06-24 | 2006-12-28 | Plt Patent & Licence Trading Ltd. | Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms |
| RU2301678C1 (ru) | 2006-05-30 | 2007-06-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения |
| CN101784869A (zh) * | 2007-05-31 | 2010-07-21 | 赫兹公司 | 为归还租赁车辆的旅客自动生成航班登机牌的系统和方法 |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US20090247466A1 (en) * | 2008-03-10 | 2009-10-01 | University Of Louisville Research Foundation | Neuroprotective integrin-binding peptide and angiopoietin-1 treatments |
| GB201700529D0 (en) | 2017-01-12 | 2017-03-01 | Rogers April | Laminin receptor peptide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993024155A1 (en) * | 1992-05-29 | 1993-12-09 | Liesi Paeivi | A nerve repair device and its use |
| US5780090A (en) * | 1995-07-26 | 1998-07-14 | Firmenich Sa | Flavored products and a process for their preparation |
| WO1999000418A1 (en) * | 1997-06-29 | 1999-01-07 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from c-reactive protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT276041B (de) * | 1968-08-16 | 1969-11-10 | Dragoco Gerberding Co Gmbh | Verfahren zur Herstellung eines konzentrierten, praktisch sterilen Rohzwiebelaromas |
| US3590722A (en) * | 1969-06-09 | 1971-07-06 | Samuel Leptrone | Flavor injector device |
| HU185263B (en) | 1981-06-12 | 1984-12-28 | Richter Gedeon Vegyeszet | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| GB9217316D0 (en) | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
| GB9324473D0 (en) | 1993-11-29 | 1994-01-12 | Oxford Res Support Co Ltd | Isolation of streptokinase by affinity chromatography |
| US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| DE19882746T1 (de) | 1997-04-03 | 2001-10-18 | California Inst Of Techn | Enzymvermittelte Modifikation von Fibrin für das Gewebs-Engineering |
| US20020168718A1 (en) * | 1997-04-03 | 2002-11-14 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
| US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
| MXPA01010692A (es) | 1999-04-22 | 2004-09-06 | Univ Zuerich | Matrices de proteina modificadas para ingenieria de tejidos o liberacion controlada. |
| DE20010297U1 (de) | 2000-06-08 | 2000-08-31 | ETH Zürich, Zürich | Enzymvermittelte Modifizierung von Fibrin zur Gewebemanipulation: Fibrin-Formulierungen mit Peptiden |
-
2001
- 2001-10-26 FI FI20012082A patent/FI20012082A0/fi unknown
-
2002
- 2002-10-25 US US10/492,850 patent/US20040266991A1/en not_active Abandoned
- 2002-10-25 WO PCT/FI2002/000831 patent/WO2003035675A1/en not_active Ceased
- 2002-10-25 DE DE60238551T patent/DE60238551D1/de not_active Expired - Lifetime
- 2002-10-25 EP EP02770017A patent/EP1438329B1/en not_active Expired - Lifetime
- 2002-10-25 AU AU2002336124A patent/AU2002336124B2/en not_active Ceased
- 2002-10-25 DK DK02770017.8T patent/DK1438329T3/da active
- 2002-10-25 AT AT02770017T patent/ATE490972T1/de not_active IP Right Cessation
- 2002-10-25 CA CA2465245A patent/CA2465245C/en not_active Expired - Fee Related
- 2002-10-25 JP JP2003538188A patent/JP4312054B2/ja not_active Expired - Fee Related
-
2005
- 2005-05-12 US US11/127,206 patent/US7659255B2/en not_active Expired - Fee Related
-
2008
- 2008-06-18 US US12/141,129 patent/US7741436B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993024155A1 (en) * | 1992-05-29 | 1993-12-09 | Liesi Paeivi | A nerve repair device and its use |
| US5780090A (en) * | 1995-07-26 | 1998-07-14 | Firmenich Sa | Flavored products and a process for their preparation |
| WO1999000418A1 (en) * | 1997-06-29 | 1999-01-07 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from c-reactive protein |
Non-Patent Citations (1)
| Title |
|---|
| Liesi et al. FEBS Lett. (1989) 224, 141-148 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040266991A1 (en) | 2004-12-30 |
| JP4312054B2 (ja) | 2009-08-12 |
| US7741436B2 (en) | 2010-06-22 |
| FI20012082A0 (fi) | 2001-10-26 |
| US7659255B2 (en) | 2010-02-09 |
| JP2005512979A (ja) | 2005-05-12 |
| ATE490972T1 (de) | 2010-12-15 |
| CA2465245A1 (en) | 2003-05-01 |
| CA2465245C (en) | 2012-09-11 |
| US20080249021A1 (en) | 2008-10-09 |
| DK1438329T3 (da) | 2011-03-28 |
| DE60238551D1 (de) | 2011-01-20 |
| EP1438329A1 (en) | 2004-07-21 |
| US20050288231A1 (en) | 2005-12-29 |
| WO2003035675A1 (en) | 2003-05-01 |
| EP1438329B1 (en) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2027152B1 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| US5093317A (en) | Treating disorders by application of insulin-like growth factor | |
| US8071549B2 (en) | Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells | |
| US7741436B2 (en) | Biologically active peptides and their use for repairing injured nerves | |
| CZ2001655A3 (cs) | Cyklický peptid, prostředek, způsob indukce myelinizace, způsob potlačení degenerace neuronů a způsob léčby | |
| CA2286291A1 (en) | Compounds and methods for inhibiting the interaction between a-catenin and b-catenin | |
| US7053046B2 (en) | Peptide activators of VEGF | |
| KR101865420B1 (ko) | 벡터적 이온 채널의 조절을 위한 유기화합물 | |
| AU2002336124A1 (en) | Biologically active peptides and their use for repairing injured nerves | |
| US20100035820A1 (en) | Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation | |
| AU2012216555B2 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| HK1128700B (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| HK1161599B (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| HK1161600B (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| HK1217346B (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |